Genetic Polymorphism of CYP2D6 and Clomiphene Concentrations in Infertile Patients with Ovulatory Dysfunction Treated with Clomiphene Citrate.
10.3346/jkms.2016.31.2.310
- Author:
Misuk JI
1
;
Kwang Rae KIM
;
Woochang LEE
;
Wonho CHOE
;
Sail CHUN
;
Won Ki MIN
Author Information
1. Department of Laboratory Medicine, Konkuk University School of Medicine, Seoul, Korea.
- Publication Type:Original Article
- Keywords:
Clomiphene;
Ovulation Induction;
Cytochrome P-450 CYP2D6
- MeSH:
Adult;
Chromatography, High Pressure Liquid;
Clomiphene/blood/metabolism/*therapeutic use;
Cytochrome P-450 CYP2D6/*genetics;
Estrogen Antagonists/analysis/metabolism/therapeutic use;
Female;
Genotype;
Humans;
Infertility/*drug therapy/genetics;
Ovulation Induction;
Phenotype;
*Polymorphism, Genetic;
Republic of Korea;
Tandem Mass Spectrometry
- From:Journal of Korean Medical Science
2016;31(2):310-314
- CountryRepublic of Korea
- Language:English
-
Abstract:
CYP2D6 is primarily responsible for the metabolism of clomiphene citrate (CC). The purpose of the present study was to investigate the relationship between CYP2D6 genotypes, concentrations of CC and its major metabolites and drug response in infertility patients. We studied 42 patients with ovulatory dysfunction treated with only CC. Patients received a dose of 100 mg/day CC on days 3-7 of the menstrual cycle. CYP2D6 genotyping and measurement of CC and the major metabolite concentrations were performed. Patients were categorized into CC responders or non-responders according to one cycle response for the ovulation. Thirty-two patients were CC responders and 10 patients were non-responders with 1 cycle treatment. The CC concentrations were highly variable within the same group, but non-responders revealed significantly lower (E)-clomiphene concentration and a trend of decreased concentrations of active metabolites compared to the responders. Nine patients with intermediate metabolizer phenotype were all responders. We confirmed that the CC and the metabolite concentrations were different according to the ovulation status. However, our results do not provide evidence for the contribution of CYP2D6 polymorphism to either drug response or CC concentrations.
